Observational study of long-term (18 month) cognitive outcomes in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimer’s disease (AD) who have previously had PET imaging with 18F-AV-45
Sponsored by Avid Radiopharmaceuticals, Inc.
18F-AV-45 is a new molecular imaging agent that may allow doctors to image changes in the brain of patients with Alzheimer’s disease using a PET (Positron Emission Tomography) scan machine. People who have previously participated in the AV-45-A05 study in which they had PET imaging with 18F-AV-45 were asked to participate in the AV-45-A11 study. The purpose of this study is to obtain information about the clinical and cognitive status of subjects 18 months after they were imaged in the previous study.
It is known that a protein peptide called amyloid-ß peptide or simply Aß accumulates in the brains of patients with Alzheimer’s disease. These accumulations are called amyloid plaques. 18F-AV-45 sticks to the amyloid plaques in the brain and emits a low level of gamma rays which can be detected by a PET camera. Therefore, it may be possible to detect amyloid plaques in patients with Alzheimer’s disease by the amount of 18F-AV-45 radioactive signal seen on a PET scan. The amount 18F-AV-45 signal in the brain detected by the PET scanner may be useful to detect Alzheimer’s disease (AD) and to predict change in cognition over time.
A total of 180 people at 24 research sites are currently taking part in this study. They will continue their participation for about 18 months.